Page 85 - MI-2-1

Microbes & Immunity Childhood brucellosis in Saudi Arabia

doi: 10.1128/JCM.40.6.2313.2002 doi: 10.1093/cid/ciad357
24. Yagupsky P, Morata P, Colmenero JD. Laboratory diagnosis 29. Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro
of human brucellosis. Clin Microbiol Rev. 2019;33(1): activities of new quinolones against Brucella melitensis
e00073-19. isolated in a tertiary-care hospital in Turkey. Clin Microbiol
Infect. 2002;8(4):240-242.
doi: 10.1128/CMR.00073-19
doi: 10.1046/j.1469-0691.2002.00416.x
25. Alavi SM, Alavi L. Treatment of brucellosis: A systematic
review of studies in recent twenty years. Caspian J Intern 30. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM,
Med. 2013;4(2):636-641. Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA.
In vitro activities of six new fluoroquinolones against Brucella
26. Stultz JS, Eiland LS. Doxycycline and tooth discoloration in
children: Changing of recommendations based on evidence melitensis. Antimicrob Agents Chemother. 1999;43(1):194-195.
of safety. Ann Pharmacother. 2019;53(11):1162-1166. doi: 10.1128/AAC.43.1.194
doi: 10.1177/1060028019863796 31. Fatani DF, Alsanoosi WA, Badawi MA, Thabit AK.
Ceftriaxone use in brucellosis: A case series. IDCases.
27. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al.
Antibiotics potentially used in response to bioterrorism and 2019;18:e00633.
the risk of major congenital malformations. Paediatr Perinat doi: 10.1016/j.idcr.2019.e00633
Epidemiol. 2009;23(1):18-28.
32. Palenque E, Otero JR, Noriega AR. In vitro susceptibility
doi: 10.1111/j.1365-3016.2008.00978.x of Brucella melitensis to new cephalosporins crossing
the blood-brain barrier. Antimicrob Agents Chemother.
28. McCreary EK, Johnson MD, Jones TM, et al. Antibiotic
myths for the infectious diseases clinician. Clin Infect Dis. 1986;29(1):182-183.
2023;77(8):1120-1125. doi: 10.1128/aac.29.1.182

Volume 2 Issue 1 (2025) 77 doi: 10.36922/mi.4634